Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001062993-25-015817
Filing Date
2025-09-26
Accepted
2025-09-26 13:17:04
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10585
2 EXHIBIT 4 exhibit4.htm EX-4 8958
  Complete submission text file 0001062993-25-015817.txt   21399
Mailing Address 1900 MARKET STREET SUITE 200 PHILADELPHIA PA 19103
Business Address 1900 MARKET STREET SUITE 200 PHILADELPHIA PA 19103 6177728515
abrdn Life Sciences Investors (Subject) CIK: 0000884121 (see all company filings)

EIN.: 043147016 | State of Incorp.: MA | Fiscal Year End: 0930
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-48561 | Film No.: 251348706

Mailing Address 405 LEXINGTON AVENUE 58TH FLOOR NEW YORK NY 10174
Business Address 405 LEXINGTON AVENUE 58TH FLOOR NEW YORK NY 10174 212-542-4635
Saba Capital Management, L.P. (Filed by) CIK: 0001510281 (see all company filings)

EIN.: 800361690 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A